Immatics logo

Immatics

IMTX | NASDAQ
Chart Builder DCF Calculator
$6.17
-$0.22 (-3.44%)
At close: Nov 16, 2026, 4:00 PM ET
$6.29
+$0.12 (+1.94%)
After-hours: Nov 16, 2026, 5:29 PM ET
-3.44%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
39.9
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #532/1021 (Top 52%)

Key Statistics

Market Data

Market Cap $923.25M
1D Range
6.07 6.57
52W Range
6.07 11.87

Valuation (TTM)

PE -3.18
PB 1.86
EV/EBITDA -2.51

Valuation (NTM)

Forward PE N/A
Forward PEG -0.41
Price Target $17.00
Loading financial charts...

Profile

Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United State...

Sector Healthcare
Industry Biotechnology
Employees 704
IPO Date Dec 12, 2018
Fiscal Year January - December

Latest News

Immatics (IMTX) Reports Q3 Loss, Lags Revenue Estimates

6 days ago · zacks.com

Immatics (IMTX) Reports Q3 Loss, Lags Revenue Estimates
Immatics Announces Third Quarter 2026 Financial Results and Business Update

6 days ago · globenewswire.com

Immatics Announces Third Quarter 2026 Financial Results and Business Update
Immatics (IMTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

8 days ago · zacks.com

Immatics (IMTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting

24 days ago · globenewswire.com

Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma

3 months ago · seekingalpha.com

Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma
Immatics Announces $150 Million Underwritten Offering

3 months ago · globenewswire.com

Immatics Announces $150 Million Underwritten Offering
Immatics Announces Second Quarter 2026 Financial Results and Business Update

3 months ago · globenewswire.com

Immatics Announces Second Quarter 2026 Financial Results and Business Update
Immatics: PRAME Is Becoming More Than A Single-Asset Story

5 months ago · seekingalpha.com

Immatics: PRAME Is Becoming More Than A Single-Asset Story
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

6 months ago · globenewswire.com

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates

6 months ago · zacks.com

Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates

Earnings

Latest Earnings
Nov 10, 2026
EPS
-$0.58
Miss -13.31%
REV
$7.82M
Miss -35.84%
Next Earnings
Mar 4, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
3
Consensus
Buy
Price Target
$17.00
Upside
+175.53%
Buy (3)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.